Market Cap 168.04M
Revenue (ttm) 2.04M
Net Income (ttm) -40.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,001.47%
Debt to Equity Ratio 1.16
Volume 2,385,206
Avg Vol 9,446,536
Day's Range N/A - N/A
Shares Out 277.80M
Stochastic %K 22%
Beta 2.45
Analysts Strong Sell
Price Target $1.79

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
Highbred
Highbred Sep. 8 at 11:15 PM
$HUMA we are in the 'use it or lose it' portion of the year for government purchases. Could use some magic here...,
0 · Reply
cdaviscamera
cdaviscamera Sep. 8 at 5:14 PM
$HUMA Nobody is arguing that further dilution is impossible. Humacyte explicitly says it expects to require additional capital. The dispute is whether that disclosure makes another near-term equity raise plus reverse split inevitable. It doesn't. The same going-concern and additional-capital language was already in the Q1 filing before V012, while HUMA subsequently went from roughly $0.60 to $1.50 without an RS. More importantly, a life-science institutional investor and long-only mutual fund led a 25-million-share offering at $0.80, and the June $1.05 offering was fully placed with the entire 15% overallotment exercised. The company's own financing history therefore demonstrates that institutional participation does not require HUMA first to reverse split. In addition to all of this, Humacyte meets all the qualifications for a 180 day compliance extension, which would effectively move the Nasdaq delisting date to sometime in July 2027.
2 · Reply
Merlintrader
Merlintrader Sep. 7 at 6:26 AM
Humacyte ($HUMA): What Comes Next for Symvess and the November Dialysis sBLA? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/humacyte-presentation-june2026-deepdive/
0 · Reply
Iwatana
Iwatana Sep. 6 at 5:24 PM
$HUMA Looks like someone hit the block button and rage quit. Guess the debate is officially over. Safe travels! 😁
1 · Reply
Iwatana
Iwatana Sep. 6 at 4:58 PM
$HUMA Teaching someone how to use AI to fetch SEC filings is surprisingly exhausting work. 😮‍💨 ​Now that he finally knows how to use it, he’s spamming entire walls of text... only for his own AI summary to end up confirming the exact same thesis I was talking about all along. Can't make this stuff up! 🤣
2 · Reply
Michael_Krombopulos
Michael_Krombopulos Sep. 6 at 4:50 PM
$HUMA not sure why a degenerate gambler bull trapped in a bad short term spot would want to attract attention to the most recent filings. They want me to buy now to rescue them and hold their bags and their defensiveness tells it all. I have a grounded opinion (based on the filings) that it’s better to wait until a clear turnaround with profitability. What a monster I am. https://investors.humacyte.com/static-files/227a1192-4db2-4d96-941c-5fdfae81c425 Revenue vs losses: $899K product revenue, $56.832M operating expenses, $55.931M operating loss. Cash burn concern: 79.903M cash, $47.165M H1 operating cash burn, explicit going-concern language Dilution and share count expansion: 3. 0M shares to 277.8M in six months, about 43.9% growth, plus authorized shares increased to 550M Financing and debt: $47.5M Lincoln Park capacity, $40M funded term loan, 11.5% minimum rate, $22.3M purchase commitments Nasdaq deficiency: Sub a dollar and has till January 27 to be back in compliance
2 · Reply
Michael_Krombopulos
Michael_Krombopulos Sep. 6 at 4:17 PM
1 · Reply
Iwatana
Iwatana Sep. 6 at 3:30 PM
$HUMA It’s always the loudest people who can’t even read an SEC filing. You swear this stock is going to zero, yet you won't touch a short position. All talk, zero risk, zero skin in the game. Pure keyboard warrior investing at its finest. 🤡
2 · Reply
Iwatana
Iwatana Sep. 6 at 3:20 PM
$HUMA Thanks for the Intro to Philosophy lecture, but StockTwits isn't a high school debate club it's a financial forum. 🤡 ​In the real market, talk is cheap and skin in the game is everything. Calling out generic noise without SEC evidence isn't a 'logical fallacy'; it's basic risk management. Notice how you wrote four paragraphs of academic excuses, yet still failed to cite a single 10-Q number or valuation metric? ​If you have facts, post the financial data. If you have conviction, short it. If you have neither, keep hiding behind dictionary definitions while the rest of us actually trade. 🥱👋
1 · Reply
Michael_Krombopulos
Michael_Krombopulos Sep. 6 at 2:47 PM
$HUMA A logical fallacy is faulty reasoning where the conclusion doesn’t actually follow from the argument. Whether someone holds a short position has nothing to do with whether their criticism of $HUMA is accurate. That’s a non sequitur and an attack on the speaker instead of their evidence. Claiming they must either short the stock or stay quiet is also a false dilemma. Someone can recognize serious risks without taking on the timing and unlimited-loss risk of shorting. Asking for SEC data is fair. Demanding a portfolio screenshot isn’t a rebuttal. Address the facts, not whether the person has money riding on them. And if they never actually claimed HUMA was going to zero, that part is a straw man too.
1 · Reply
Latest News on HUMA
Humacyte publishes V007 results in The Lancet Digital Health

2026-08-19T12:10:09.000Z - 20 days ago

Humacyte publishes V007 results in The Lancet Digital Health


Humacyte reports Q2 EPS (16c), consensus (10c)

2026-08-17T09:58:11.000Z - 22 days ago

Humacyte reports Q2 EPS (16c), consensus (10c)


Humacyte price target lowered to $1 from $2 at Benchmark

2026-08-17T07:52:22.000Z - 22 days ago

Humacyte price target lowered to $1 from $2 at Benchmark


Humacyte Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 27 days ago

Humacyte Earnings Call Transcript: Q2 2026


Humacyte Earnings release: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 27 days ago

Humacyte Earnings release: Q2 2026


Humacyte Quarterly report: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 27 days ago

Humacyte Quarterly report: Q2 2026


Humacyte announces FDA acceptance of CTEV IND application

2026-07-27T12:25:48.000Z - 6 weeks ago

Humacyte announces FDA acceptance of CTEV IND application


Humacyte price target lowered to $1.25 from $1.50 at TD Cowen

2026-06-17T12:32:32.000Z - 2 months ago

Humacyte price target lowered to $1.25 from $1.50 at TD Cowen


Humacyte Slides: Corporate presentation

Jun 16, 2026, 3:00 PM EDT - 2 months ago

Humacyte Slides: Corporate presentation


Humacyte Transcript: Study result

Jun 15, 2026, 5:00 PM EDT - 2 months ago

Humacyte Transcript: Study result


Humacyte Press release: Study result

Jun 15, 2026, 5:00 PM EDT - 2 months ago

Humacyte Press release: Study result


Humacyte price target raised to $4 from $3 at H.C. Wainwright

2026-06-11T13:47:07.000Z - 2 months ago

Humacyte price target raised to $4 from $3 at H.C. Wainwright


Humacyte 47.62M share Spot Secondary priced at $1.05

2026-06-11T01:35:07.000Z - 3 months ago

Humacyte 47.62M share Spot Secondary priced at $1.05


Humacyte TBA Spot Secondary; price range $1.05-$1.15

2026-06-10T22:15:08.000Z - 3 months ago

Humacyte TBA Spot Secondary; price range $1.05-$1.15


Humacyte announces V012 study of ATEV meets primary endpoint

2026-06-10T20:14:24.000Z - 3 months ago

Humacyte announces V012 study of ATEV meets primary endpoint


Humacyte announces common stock offering, no amount given

2026-06-10T20:10:11.000Z - 3 months ago

Humacyte announces common stock offering, no amount given


Humacyte Transcript: AGM 2026

Jun 9, 2026, 8:00 AM EDT - 3 months ago

Humacyte Transcript: AGM 2026


Humacyte price target raised to $2 from $1 at Benchmark

2026-06-01T11:58:24.000Z - 3 months ago

Humacyte price target raised to $2 from $1 at Benchmark


Humacyte price target raised to $1.50 from $1 at TD Cowen

2026-05-14T15:08:47.000Z - 3 months ago

Humacyte price target raised to $1.50 from $1 at TD Cowen


Humacyte reports Q1 EPS (9c), consensus (12c)

2026-05-13T13:00:50.000Z - 3 months ago

Humacyte reports Q1 EPS (9c), consensus (12c)


Humacyte Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Humacyte Earnings Call Transcript: Q1 2026


Humacyte Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Humacyte Earnings release: Q1 2026


Humacyte Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Humacyte Quarterly report: Q1 2026


Humacyte names Todd Rasmussen chief surgical officer

2026-05-12T15:32:56.000Z - 3 months ago

Humacyte names Todd Rasmussen chief surgical officer


Humacyte Transcript: KOL event

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Humacyte Transcript: KOL event


Humacyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Humacyte Proxy statement: Proxy filing


Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Humacyte Appoints Jim Mercadante as Chief Commercial Officer


Humacyte Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Humacyte Proxy statement: Proxy filing


Humacyte Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Humacyte Earnings Call Transcript: Q4 2025


Humacyte Annual report: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Humacyte Annual report: Q4 2025


Humacyte Earnings release: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Humacyte Earnings release: Q4 2025


Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 6 months ago

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference


Humacyte To Participate in Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 6 months ago

Humacyte To Participate in Upcoming Investor Conferences


Humacyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Humacyte Earnings Call Transcript: Q3 2025


Humacyte Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Humacyte Quarterly report: Q3 2025


Humacyte Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Humacyte Earnings release: Q3 2025


Humacyte Registration statement: Registration Filing

Sep 12, 2025, 8:00 AM EDT - 12 months ago

Humacyte Registration statement: Registration Filing


Humacyte Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q2 2025


Humacyte Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Quarterly report: Q2 2025


Humacyte Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Earnings release: Q2 2025


Highbred
Highbred Sep. 8 at 11:15 PM
$HUMA we are in the 'use it or lose it' portion of the year for government purchases. Could use some magic here...,
0 · Reply
cdaviscamera
cdaviscamera Sep. 8 at 5:14 PM
$HUMA Nobody is arguing that further dilution is impossible. Humacyte explicitly says it expects to require additional capital. The dispute is whether that disclosure makes another near-term equity raise plus reverse split inevitable. It doesn't. The same going-concern and additional-capital language was already in the Q1 filing before V012, while HUMA subsequently went from roughly $0.60 to $1.50 without an RS. More importantly, a life-science institutional investor and long-only mutual fund led a 25-million-share offering at $0.80, and the June $1.05 offering was fully placed with the entire 15% overallotment exercised. The company's own financing history therefore demonstrates that institutional participation does not require HUMA first to reverse split. In addition to all of this, Humacyte meets all the qualifications for a 180 day compliance extension, which would effectively move the Nasdaq delisting date to sometime in July 2027.
2 · Reply
Merlintrader
Merlintrader Sep. 7 at 6:26 AM
Humacyte ($HUMA): What Comes Next for Symvess and the November Dialysis sBLA? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/humacyte-presentation-june2026-deepdive/
0 · Reply
Iwatana
Iwatana Sep. 6 at 5:24 PM
$HUMA Looks like someone hit the block button and rage quit. Guess the debate is officially over. Safe travels! 😁
1 · Reply
Iwatana
Iwatana Sep. 6 at 4:58 PM
$HUMA Teaching someone how to use AI to fetch SEC filings is surprisingly exhausting work. 😮‍💨 ​Now that he finally knows how to use it, he’s spamming entire walls of text... only for his own AI summary to end up confirming the exact same thesis I was talking about all along. Can't make this stuff up! 🤣
2 · Reply
Michael_Krombopulos
Michael_Krombopulos Sep. 6 at 4:50 PM
$HUMA not sure why a degenerate gambler bull trapped in a bad short term spot would want to attract attention to the most recent filings. They want me to buy now to rescue them and hold their bags and their defensiveness tells it all. I have a grounded opinion (based on the filings) that it’s better to wait until a clear turnaround with profitability. What a monster I am. https://investors.humacyte.com/static-files/227a1192-4db2-4d96-941c-5fdfae81c425 Revenue vs losses: $899K product revenue, $56.832M operating expenses, $55.931M operating loss. Cash burn concern: 79.903M cash, $47.165M H1 operating cash burn, explicit going-concern language Dilution and share count expansion: 3. 0M shares to 277.8M in six months, about 43.9% growth, plus authorized shares increased to 550M Financing and debt: $47.5M Lincoln Park capacity, $40M funded term loan, 11.5% minimum rate, $22.3M purchase commitments Nasdaq deficiency: Sub a dollar and has till January 27 to be back in compliance
2 · Reply
Michael_Krombopulos
Michael_Krombopulos Sep. 6 at 4:17 PM
1 · Reply
Iwatana
Iwatana Sep. 6 at 3:30 PM
$HUMA It’s always the loudest people who can’t even read an SEC filing. You swear this stock is going to zero, yet you won't touch a short position. All talk, zero risk, zero skin in the game. Pure keyboard warrior investing at its finest. 🤡
2 · Reply
Iwatana
Iwatana Sep. 6 at 3:20 PM
$HUMA Thanks for the Intro to Philosophy lecture, but StockTwits isn't a high school debate club it's a financial forum. 🤡 ​In the real market, talk is cheap and skin in the game is everything. Calling out generic noise without SEC evidence isn't a 'logical fallacy'; it's basic risk management. Notice how you wrote four paragraphs of academic excuses, yet still failed to cite a single 10-Q number or valuation metric? ​If you have facts, post the financial data. If you have conviction, short it. If you have neither, keep hiding behind dictionary definitions while the rest of us actually trade. 🥱👋
1 · Reply
Michael_Krombopulos
Michael_Krombopulos Sep. 6 at 2:47 PM
$HUMA A logical fallacy is faulty reasoning where the conclusion doesn’t actually follow from the argument. Whether someone holds a short position has nothing to do with whether their criticism of $HUMA is accurate. That’s a non sequitur and an attack on the speaker instead of their evidence. Claiming they must either short the stock or stay quiet is also a false dilemma. Someone can recognize serious risks without taking on the timing and unlimited-loss risk of shorting. Asking for SEC data is fair. Demanding a portfolio screenshot isn’t a rebuttal. Address the facts, not whether the person has money riding on them. And if they never actually claimed HUMA was going to zero, that part is a straw man too.
1 · Reply
bioman2024
bioman2024 Sep. 5 at 10:00 PM
$HUMA … a partnership at this point keeps them more or less in the game for good.
0 · Reply
bioman2024
bioman2024 Sep. 5 at 5:24 PM
$HUMA …”collaborations, strategic alliances” > what I would like to see. Like why not. It would solve so many issues.
0 · Reply
Iwatana
Iwatana Sep. 5 at 4:30 PM
If you’re so utterly convinced $HUMA is going to zero, put your money where your mouth is and show us your short position. Real conviction comes with receipts, not endless free comments on stock forums. Post the position, back it up with SEC data, and shut me up once and for all. Otherwise, it’s just loud noise with zero skin in the game.
0 · Reply
Iwatana
Iwatana Sep. 5 at 4:24 PM
It’s always the same script from the keyboard bears: “dilution machine,” “reverse split,” “it’s cooked.” 🥱 ​Notice how none of them ever post actual SEC numbers, cash runway data, or institutional filings? Just pure emotional noise and zero skin in the game. ​If you’re going to be bearish, at least bring real financial metrics or 10-Q references to the table. Blindly repeating generic FUD headlines just proves you haven't done any actual DD. $HUMA
1 · Reply
mplaster
mplaster Sep. 5 at 10:52 AM
$HUMA it's fair to say this stock is cooked .... It's just a dilution machine for owners to pay them selfs big .... This will r.s ...and dilute down.
1 · Reply
Weightgain2000
Weightgain2000 Sep. 4 at 10:56 PM
$HUMA When people call this a penny stock , they mean penny I once thought this company would be big a couple of years ago. Management just selling their shares every time they released news the news that they release these days are the same from a few years ago and they call it new. They even have the dates of several years ago on the charts as part of the current news. a total ripe off for salary. the promise of filing in November is from a failed trial from 3 years ago. It was for both men and women and since it failed they said that a subset may be possible for women only. Had very bad results at the time. Look before the reverse split that has to happen.
3 · Reply
Iwatana
Iwatana Sep. 4 at 9:28 PM
Closing the week above $0.60. Is it ideal? Obviously not. HUMA is still consolidating in a lower price zone, and we haven't seen the breakout we want yet. But considering the macro pressure and Fed rate uncertainty weighing on high beta biotech stocks, holding the $0.60 area without breaking down to fresh recent lows is still a respectable technical setup. For now, I’m more interested in whether HUMA can reclaim $0.61–$0.65 with meaningful volume than in chasing short term noise. The real story remains the upcoming catalysts especially the planned ATEV supplemental BLA for dialysis access and the continued commercialization of Symvess. Enjoy the weekend. Let the macro noise settle, stay patient, and keep the focus on the thesis. ☕️🍿 $HUMA
2 · Reply
Wolf1971
Wolf1971 Sep. 4 at 3:10 PM
$HUMA reminder: cabg is the single most expensive procedure in the world from a macro perspective. HUMA about to provide the biggest advance since use of Lima graft became standard in 1980s
1 · Reply
LostinNikla
LostinNikla Sep. 3 at 11:09 PM
$HUMA Crowbaby.... Very well Done/Summary of important dates, I have it saved on my phone, again thank You
2 · Reply
mplaster
mplaster Sep. 3 at 2:43 PM
$HUMA 0.58 man pos
0 · Reply
Iwatana
Iwatana Sep. 3 at 1:50 AM
$HUMA U.S. Treasury buying back up to $12.5B in bonds today (Sept 3) between 1:40–2:00 PM EDT. Macro Effect: Injects liquidity into the market, caps Treasury yields, and provides a short-term tailwind for Growth and Small cap Biotech sectors. $HUMA Impact: Offers macro driven tailwinds, but execution on BLA and upcoming FDA milestones remain the primary drivers for a sustained breakout.
0 · Reply
crowbaby333
crowbaby333 Sep. 3 at 1:32 AM
$HUMA forgive the summary but there is still a strong history / bull case here
2 · Reply